IP Library Granted Patent US 10,640,535
Granted Patent B2
US 10,640,535 · App. 14/403,350 · Granted May 5, 2020

Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

Inventors: Donald F. Hunt (Charlottesville, VA); Andrew Norris (Palmyra, VA); Ann Michelle English (Palmyra, VA); Jeffrey Shabanowitz (Charlottesville, VA); William H. Hilderbrand (Edmond, OK); Oriana E. Hawkins (Tuscola, TX)
Assignees: AGENUS INC.; THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
C07K7/08A61K39/0011C07K7/06C07K14/4748C07K16/18A61K38/00C07K2317/24C07K2317/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,640,535
App. No.
14/403,350
Granted
May 5, 2020
Kind
B2
Abstract

The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.

Claims (106)

1. A composition comprising:

(a) an isolated or synthetic phosphopeptide having a length of 10 to 30 amino acids and comprising a sequence selected from the group consisting of:

SEQ ID NO: 132;

SEQ ID NO: 132 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 71 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 72 wherein the serine at the eighth position is phosphorylated;

SEQ ID NO: 73 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 75 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 76 wherein the serine at the eighth position is phosphorylated;

SEQ ID NO: 78 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 79 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 80 wherein the threonine at the third position is phosphorylated;

SEQ ID NO: 84 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 87 wherein the serine at the eighth position is phosphorylated;

SEQ ID NO: 93 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 94 wherein the serine at the fifth position is phosphorylated;

SEQ ID NO: 97 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 99 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 100 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 101 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 102 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 104 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 105 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 110 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 112 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 113 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 114 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 115 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 117 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 118 wherein the serine at the tenth position is phosphorylated;

SEQ ID NO: 120 wherein the threonine at the fourth position is phosphorylated;

SEQ ID NO: 126 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 127 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 135 wherein the serine at the sixth position is phosphorylated;

SEQ ID NO: 140 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 143 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 145 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 146 wherein the tyrosine at the fifth position is phosphorylated;

SEQ ID NO: 149 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 151 wherein the serine at the eighth position is phosphorylated;

SEQ ID NO: 153 wherein the serine at the seventh position is phosphorylated;

SEQ ID NO: 154 wherein the serine at the fifth position is phosphorylated;

SEQ ID NO: 160 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 161 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 162 wherein the serine at the fourth position is phosphorylated and the serine at the eighth position is phosphorylated;

SEQ ID NO: 163 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 166 wherein the serine at the seventh position is phosphorylated;

SEQ ID NO: 167 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 168 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 169 wherein the serine at the fourth position is phosphorylated;

SEQ ID NO: 170 wherein the serine at the seventh position is phosphorylated, and

(b) an adjuvant.

2. The composition of claim 1 , wherein said composition has the ability to stimulate a T cell mediated immune response to at least one of said phosphopeptides.

3. The composition of claim 1 , comprising a peptide capable of binding to the HLA-B*0702 allele on the MHC class I molecule.

4. A method of inducing an immunogenic response comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 1 .

5. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 1 .

6. A method of treating breast cancer comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 1 .

7. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 132.

8. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 132, wherein the serine at the fourth position is phosphorylated.

9. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 71, wherein the serine at the fourth position is phosphorylated.

10. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 72, wherein the serine at the eighth position is phosphorylated.

11. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 73, wherein the serine at the sixth position is phosphorylated.

12. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 75, wherein the serine at the sixth position is phosphorylated.

13. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 76, wherein the serine at the eighth position is phosphorylated.

14. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 78, wherein the serine at the sixth position is phosphorylated.

15. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 79, wherein the serine at the fourth position is phosphorylated.

16. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 80, wherein the threonine at the third position is phosphorylated.

17. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 84, wherein the serine at the fourth position is phosphorylated.

18. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 87, wherein the serine at the eighth position is phosphorylated.

19. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 93, wherein the serine at the fourth position is phosphorylated.

20. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 94, wherein the serine at the fifth position is phosphorylated.

21. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 97, wherein the serine at the fourth position is phosphorylated.

22. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 99, wherein the serine at the sixth position is phosphorylated.

23. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 100, wherein the serine at the fourth position is phosphorylated.

24. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 101, wherein the serine at the sixth position is phosphorylated.

25. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 102, wherein the serine at the fourth position is phosphorylated.

26. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 104, wherein the serine at the sixth position is phosphorylated.

27. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 105, wherein the serine at the fourth position is phosphorylated.

28. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 110, wherein the serine at the fourth position is phosphorylated.

29. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 112, wherein the serine at the fourth position is phosphorylated.

30. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 113, wherein the serine at the fourth position is phosphorylated.

31. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 114, wherein the serine at the fourth position is phosphorylated.

32. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 115, wherein the serine at the fourth position is phosphorylated.

33. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 117, wherein the serine at the sixth position is phosphorylated.

34. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 118, wherein the serine at the tenth position is phosphorylated.

35. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 120, wherein the threonine at the fourth position is phosphorylated.

36. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 126, wherein the serine at the sixth position is phosphorylated.

37. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 127, wherein the serine at the sixth position is phosphorylated.

38. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 135, wherein the serine at the sixth position is phosphorylated.

39. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 140, wherein the serine at the fourth position is phosphorylated.

40. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 143, wherein the serine at the fourth position is phosphorylated.

41. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 145, wherein the serine at the fourth position is phosphorylated.

42. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 146, wherein the tyrosine at the fifth position is phosphorylated.

43. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 149, wherein the serine at the fourth position is phosphorylated.

44. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 151, wherein the serine at the eighth position is phosphorylated.

45. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 153, wherein the serine at the seventh position is phosphorylated.

46. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 154, wherein the serine at the fifth position is phosphorylated.

47. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 160, wherein the serine at the fourth position is phosphorylated.

48. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 161, wherein the serine at the fourth position is phosphorylated.

49. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 162, wherein the serine at the fourth position is phosphorylated and the serine at the eighth position is phosphorylated.

50. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 163, wherein the serine at the fourth position is phosphorylated.

51. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 166, wherein the serine at the seventh position is phosphorylated.

52. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 167, wherein the serine at the fourth position is phosphorylated.

53. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 168, wherein the serine at the fourth position is phosphorylated.

54. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 169, wherein the serine at the fourth position is phosphorylated.

55. The composition of claim 1 , wherein the at least one synthetic target peptide comprises the amino acid sequence as set forth in SEQ ID NO: 170, wherein the serine at the seventh position is phosphorylated.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2016
From: UNIVERSITY OF VIRGINIA
To: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, D/B/A UNIVERSITY OF VIRGINIA LICENSING & VENTURES GROUP
Reel/Frame 037442/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2016
From: HUNT, DONALD F.; SHABANOWITZ, JEFFREY; ENGLISH, ANN MICHELLE; NORRIS, ANDREW
To: PHOSIMMUNE, INC.
Reel/Frame 037442/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2016
From: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, D/B/A UNIVERSITY OF VIRGINIA LICENSING AND VENTURES GROUP
To: HUNT, DONALD F.; SHABANOWITZ, JEFFREY; ENGLISH, ANN MICHELLE; NORRIS, ANDREW
Reel/Frame 037433/0378 →
MERGER Recorded Jan 7, 2016
From: PHOSIMMUNE INC.
To: AGENUS INC.
Reel/Frame 037429/0703 →
CONFIRMATORY LICENSE Recorded Dec 16, 2015
From: UNIVERSITY OF VIRGINIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037302/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2015
From: HUNT, DONALD F.; SHABANOWITZ, JEFFREY; NORRIS, ANDREW; ENGLISH, ANN M.
To: PHOSIMMUNE INC.
Reel/Frame 035107/0013 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2015
From: HAWKINS, ORIANA E.; HILDERBRAND, WILLIAM H.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
Reel/Frame 035106/0915 →
Continuity (3)
Provisional Application 61652028 · May 25, 2012
Provisional Application 61667697 · Jul 3, 2012
Related Publication 20150225456A1 · Aug 13, 2015